Pharma Focus Asia

Inflection Biosciences Announces Research Collaboration with MD Anderson

Friday, November 02, 2018

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”). The collaboration aims to explore the effects of the company’s pipeline of potential cancer treatments, including its first-in-class, dual mechanism PIM/PI3K inhibitors, in head and neck cancer.

The research will be carried out at the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson, by Professors Xiuning Le and Maura Gillison. Professor Gillison, a head and neck medical oncologist and molecular epidemiologist, was the first to make the association of human papillomavirus (HPV) in head and neck cancer. She is a leading expert on HPV and oral cancer. Her work also points to a crucial role for PIM and PI3K in the origin and development of certain head and neck cancers.

Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences commented, “We are excited to announce this collaboration with MD Anderson. The team involved in this research are leaders in the field of head and neck cancer research and will enhance our understanding of the potential for our treatments in cancer patients.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024